These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
305 related items for PubMed ID: 1184747
1. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. Myers CE, Young RC, Chabner BA. J Clin Invest; 1975 Nov; 56(5):1231-8. PubMed ID: 1184747 [Abstract] [Full Text] [Related]
2. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Berger SH, Hakala MT. Mol Pharmacol; 1984 Mar; 25(2):303-9. PubMed ID: 6608049 [Abstract] [Full Text] [Related]
3. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Spears CP, Gustavsson BG, Berne M, Frösing R, Bernstein L, Hayes AA. Cancer Res; 1988 Oct 15; 48(20):5894-900. PubMed ID: 3167844 [Abstract] [Full Text] [Related]
4. On the rational development of a new drug: the example of the fluorinated pyrimidines. Heidelberger C. Cancer Treat Rep; 1981 Oct 15; 65 Suppl 3():3-9. PubMed ID: 7346154 [Abstract] [Full Text] [Related]
7. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor. Myers CE, Young RC, Chabner BA. Cancer Res; 1976 May 15; 36(5):1653-8. PubMed ID: 1268826 [Abstract] [Full Text] [Related]
10. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ. Clin Cancer Res; 1999 Mar 15; 5(3):643-54. PubMed ID: 10100718 [Abstract] [Full Text] [Related]
11. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo]. Nakamura H, Yu-Qin W, Miyauchi S, Nishioka N, Tanaka H, Harada N, Shirasaka T, Fujii S. Gan To Kagaku Ryoho; 1984 May 15; 11(5):1049-55. PubMed ID: 6426401 [Abstract] [Full Text] [Related]
12. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. Ren Q, Van Groeningen CJ, Hardcastle A, Aherne GW, Geoffroy F, Allegra CJ, Johnston PG, Grem JL. Oncol Res; 1997 May 15; 9(2):77-88. PubMed ID: 9167189 [Abstract] [Full Text] [Related]
13. Biphasic binding of 5-fluoro-2'-deoxyuridylate to human thymidylate synthase. Reilly RT, Barbour KW, Dunlap RB, Berger FG. Mol Pharmacol; 1995 Jul 15; 48(1):72-9. PubMed ID: 7623777 [Abstract] [Full Text] [Related]
14. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Houghton JA, Maroda SJ, Phillips JO, Houghton PJ. Cancer Res; 1981 Jan 15; 41(1):144-9. PubMed ID: 7448754 [Abstract] [Full Text] [Related]
17. Development, characterization and application of an antibody against 5-fluoro-2'deoxyuridine-5'monophosphate, the active metabolite of 5-fluorouracil. Peters GJ, Laurensse E, Steinbusch HW, De Vente J, Smid K, Van der Wilt CL, Pinedo HM. Anticancer Res; 1993 Jan 15; 13(4):835-9. PubMed ID: 8352551 [Abstract] [Full Text] [Related]